ReviewsDrug-induced Fanconi's syndrome
References (0)
Cited by (204)
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia
2024, Best Practice and Research: Clinical Endocrinology and MetabolismOverview of Antibiotic-Induced Nephrotoxicity
2023, Kidney International ReportsLack of xanthine dehydrogenase leads to a remarkable renal decline in a novel hypouricemic rat model
2022, iScienceCitation Excerpt :Clinical conditions presenting with hypouricemia can be classified as disorders of decreased UA production or increased UA urinary excretion (hyperuricosuria) (Pineda et al., 2019). In both categories, there are inherited conditions (hereditary xanthinuria, purine nucleoside phosphorylase deficiency, hereditary renal hypouricemia types 1 & 2 (RHUC1 & 2)) as well as acquired disorders (overcorrection by UA-lowering therapy, liver disease (Michelis et al., 1974), malnutrition, Fanconi syndrome (Izzedine et al., 2003), diabetes mellitus, and so forth) resulting in hypouricemia. Although most clinical cases of hypouricemia present asymptomatically, some complications such as acute kidney injury (AKI) (Ichida et al., 2004; Ishikawa et al., 1990; Ohta et al., 2004), nephrolithiasis, and posterior reversible encephalopathy syndrome have been reported (Fujinaga et al., 2013).
Fanconi syndrome and euglycemic diabetic ketoacidosis secondary to canagliflozin use in a type 2 diabetic
2022, Journal of Clinical and Translational Endocrinology: Case ReportsZoledronic Acid–Associated Fanconi Syndrome in Patients With Cancer
2022, American Journal of Kidney DiseasesRenal toxicity of anticancer drugs
2021, Nephrologie et Therapeutique